AlloMap Molecular Expression Testing

New from XDx – Announcing…

AlloMap molecular expression testing is now available for cardiac transplants as early as 2 months post cardiac transplant!

For cardiac transplant patients, acute cellular rejection is most worrisome in the first months post transplant. As of Monday, August 21, 2006, AlloMap molecular expression testing is available to help you monitor patients as early as 2 months post cardiac transplant. When combined with patient assessment, AlloMap testing can provide the confidence you need to rule out acute cellular rejection.

Freedom from Future Rejection

A CARGO sub-study showed that patients with scores < 20 in the first 6 months post transplant were free from ACR ≥ 3A(2R) for the next 80 days (~12 weeks)¹.

¹ Data on File

Transplant Clinic

Patients & Families

Lab Professionals

Discover XDx

Clinical Labs

Font Size:

	AlloMap Testing Overview
	AlloMap Testing Process
	Order Supplies
	AlloMap Sample Preparation Training
	Billing

XDx Reference Laboratory Certification Information

Lab Directors:
Patrick Joseph, MD
Judith Wilber, PhD, D(ABMM)

CLIA Number: 05D1029609

California License
(CLF) Number: 332008

The AlloMap Molecular Expression Testing Process

The figure below illustrates the process for AlloMap molecular expression testing. When patients are monitored using AlloMap testing, they come to the medical center for a simple blood draw. The sample is prepared and sent to the XDx Reference Laboratory, where it is analyzed. After the gene expression data is translated, the result is reported to the physician, who determines the next steps for the patient.

Note: In most circumstances, The XDx Reference Laboratory bills the patient’s insurance company directly. Click here to learn more about billing for AlloMap Testing.

AlloMap testing process